What role does CYP2D6 play in allergy?

CYP2D6 is a key drug-metabolizing enzyme (phase I) that processes many medications and some endogenous compounds. In the context of allergies, its role is primarily indirect: it metabolizes antihistamines (e.g., loratadine, desloratadine) and other drugs used in allergy treatment. Genetic variants in CYP2D6 can cause poor, intermediate, or ultrarapid metabolism, altering drug efficacy and side effect profiles. Some observational studies have suggested links between CYP2D6 polymorphisms and susceptibility to asthma or atopic diseases, but effect sizes are small and findings inconsistent. No large GWAS have established CYP2D6 as a major allergy risk gene. Therefore, the main practical application is pharmacogenetic: testing can guide dosing of CYP2D6-substrate drugs, but it should not be used as a standalone allergy risk predictor. Evidence is mechanistic/pharmacokinetic, not directly from allergy challenge studies. Caveat: Commercial allergy tests typically measure IgE or skin responses, not CYP2D6 genotype. Consumers should not interpret a CYP2D6 variant as a direct cause of allergies.